Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Inclusion Criteria11

• Female and male patients diagnosed with one of the following:
• Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions
• Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years
• Non-breast cancer patients exposed to other anticancer therapies within the past 3 years
• Washout from investigational interventions is up to the discretion of the Investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.
• ≥18 years of age
• Perceived by patient or investigator that cognitive function has worsened since cancer diagnosis and/or beginning of cancer treatment
• Able to provide informed consent.
• Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.
• Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.
• Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.